We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.
- Authors
Voce, David J.; Bernal, Giovanna M.; Cahill, Kirk E.; Wu, Longtao; Mansour, Nassir; Crawley, Clayton D.; Campbell, Paige-Ashley S.; Arina, Ainhoa; Weichselbaum, Ralph R.; Yamini, Bakhtiar
- Abstract
The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM). The anti-glioma effect of TMZ involves a complex response that includes G2-M cell cycle arrest and cyclin-dependent kinase 1 (CDK1) activation. While CDK1 phosphorylation is a well-described consequence of TMZ treatment, we find that TMZ also robustly induces CDK1 expression. Analysis of this pathway demonstrates that CDK1 is regulated by NF-κB via a putative κB-site in its proximal promoter. CDK1 was induced in a manner dependent on mature p50 and the atypical inhibitor κB protein, BCL-3. Treatment with TMZ induced binding of NF-κB to the κB-site as assessed by gel shift analysis and chromatin immunoprecipitation. Examination of a CDK1 promoter-reporter demonstrated the functional relevance of the κB-site and underlined the requirement of p50 and BCL-3 for activation. Targeted knockdown of CDK1 or chemical inhibition with the selective CDK1 inhibitor, RO-3306, potentiated the cytotoxic effect of TMZ. These results identify CDK1 as an NF-κB target gene regulated by p50 and BCL-3 and suggest that targeting CDK1 may be a strategy to improve the efficacy of TMZ against GBM.
- Subjects
CYCLIN-dependent kinases; TEMOZOLOMIDE; TRANSCRIPTION factors; GLIOBLASTOMA multiforme; PHOSPHORYLATION
- Publication
Scientific Reports, 2021, Vol 11, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-021-84912-4